Evaluation of costs in rheumatic diseases: A literature review

Current Opinion in Rheumatology

Volumn 11, Issue 2, 1999, Pages 104-109

  Ruof, Jörg ^a   Hülsemann, Jan L ^a   Stucki, Gerold ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTHROPLASTY; COST BENEFIT ANALYSIS; DATA ANALYSIS; ECONOMIC ASPECT; HUMAN; OSTEOARTHRITIS; PHARMACOECONOMICS; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; UNITED STATES;

ARTHRITIS, RHEUMATOID; HEALTH CARE COSTS; HUMANS; OSTEOARTHRITIS; UNITED STATES;

EID: 0032788368     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199903000-00004     Document Type: Review

References (29)

1. 1 Drummond MF, Stoddart GL, Torrance GW (eds): Critical assessment of economic evaluation. In: Methods for the Economic Evaluation of Health Care Programmes. Oxford, UK:Oxford University Press; 1990:18-35.
2. 2 Department of Clinical Epidemiology and Biostatistics, Mc Master University Health Sciences Centre: How to read clinical journals: VII. To understand an economic evaluation (part A). Can Med Assoc J 1984, 130:1428-1434.
3. 3 Boers M, Brooks P, Strand V, Tugwell P: The OMERACT filter for outcome measures in rheumatology. J Rheumtol 1998, 25:198-199.
4. 4 Spilker B (ed): Developing guidelines for pharmacoeconomic trials. In: Quality of Life and Pharmacoeconomics in Clinical Trials, edn 2. Philadelphia:Lippincott-Raven; 1996:1123-1130.
5. 5 Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB, for the Panel on Cost-Effectiveness in Health and Medicine: Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996, 276:1253-1258.
6. 6 Rothfuss J, Mau W, Zeidler H, Brenner MH: Socioeconomic evaluation of rheumatoid arthritis and osteoarthritis: a literature review. Semin Arthritis Rheum 1997, 26:771-779.
7. 7 Ferraz MB, Maetzel A, Bombardier C: A summary of economic evaluations published in the field of rheumatology and related disciplines. Arthritis Rheum 1997, 40:1587-1593.
8. 8 Ariza-Ariza R, Mestanza-Peralta M, Cardiel MH: Direct costs of medical attention to Mexican patients with rheumatoid arthritis in a tertiary care center. Clin Exp Rheumatol 1997, 15:75-78.
9. 9 Clarke AE, Zowall H, Levinton C, Assimakopoulos H, Sibley JT, Haga M, et al.: Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 1997, 24:1051-1060. The authors present the first prospective longitudinal 12-year follow-up study of direct and indirect costs of rheumatoid arthritis in a Canadian study sample. After presenting a comprehensive set of cost-data, the authors conclude that direct costs exceed indirect costs.
10. 10 Cronan TA, Durkin KA, Groessl E, Tomita M: Health care costs for volunteers and non-volunteers in an intervention for people with osteoarthritis. Arthritis Care Res 1997, 10:36-42.
11. 11 Gabriel SE, Crowson CS, Campion ME, O'Fallon WM: Direct medical costs unique to people with arthritis. J Rheumatol 1997, 24:719-725. This report presents a comprehensive analysis of disease-related and nonrelated direct medical costs in people with arthritis. The results underline the relevance of including all direct medical costs rather than only disease-specific costs.
12. 12 Gabriel SE, Crowson CS, Campion ME, O'Fallon WM: Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol 1997, 24:43-48. Data from various sources were assembled and reveal that indirect and nonmedical costs of osteoarthritis approach those of rheumatoid arthritis.
13. 13 Kochevar RJ, Kaplan RM, Weisman M: Financial and career losses due to rheumatoid arthritis: a pilot study. J Rheumatol 1997, 24:1527-1530. This report introduces a novel model of estimating loss of income based on job histories and functional performance of patients with rheumatoid arthritis.
14. 14 Lambert CM, Hurst NP, Forbes JF, Lochhead A, Macleod M, Nuki G: Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomized controlled clinical and economic evaluation. Br Med J 1998, 316:965-969. This well-designed cost-minimization analysis compares Inpatient care and day care in patients with rheumatoid arthritis. The data suggest an equivalent clinical outcome in both study groups, with a slight advantage in costing in terms of day care.
15. 15 Lanes SF, Lanza LL, Radensky PW, Yood RA, Meenan RF, Walker AM, Dreyer NA: Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthritis Rheum 1997, 40:1475-1481. This study assesses the direct costs of rheumatoid arthritis and osteoarthritis care in a managed care setting. Because of its greater prevalence, osteoarthritis is seven times more costly in this setting than rheumatoid arthritis.
16. 16 Maetzel A, Ferraz MB, Bombardier C: The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1998, 41:16-25. This carefully designed decision-analysis model estimates the cost-effectiveness of misoprostol in preventing nonsteroidal anti-inflammatory drug-induced gastropathy in a rheumatoid arthritis population with low, medium (history of peptic ulcer disease), and high (history of peptic ulcer disease and age >75) risk.
17. 17 Skagren EI, Öberg BE, Carlsson PG, Gade M: Cost and effectiveness analysis of chiropractic and physiotherapy treatment for low back and neck pain. Spine 1997, 22:2167-2177.
18. 18 Watson PJ, Main CJ, Waddell G, Gales TF, Purcell-Jones G: Medically certified work loss, recurrence and costs of wage compensation for back pain: a follow-up study of the working population of Jersey. Br J Rheumatol 1998, 37:82-87.
19. 19 Strickland GT, Karp AC, Mathews A, Pena CA: Utilization and cost of serologic tests for Lyme disease in Maryland. J Infect Dis 1997, 176:819-821.
20. 20 Wilson L: Cost-of illness of scleroderma: the case for rare diseases. Semin Arthritis Rheum 1997, 27:73-84. This study provides a model for estimation of rare disease costs. Despite low prevalence, the authors reported annual direct and indirect costs of scleroderma in the United States of $1.5 billion.
21. 21 Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg DL, et al.: A prospective, longitudinal, multicenter study of service utilization and costs in flbromyalgia. Arthritis Rheum 1997, 40:1560-1570. The authors found high rates of service utilization in fibromyalgia patients leading to average annual per-patient costs of $2274.
22. 22 Stadtmauer G, Cunningham-Rundles C: Outcome analysis and cost assessment in immunologic disorders. JAMA 1997, 278:2018-2023.
23. 23 Brader VA, Malhotra S, Jet J, Heinemann AW, Stulberg SD: Outcome of hip and knee arthroplasty in persons aged 80 years and older. Clin Orthop 1997, 345:67-78.
24. 24 Healy WL, lorio R, Richards JA: Opportunities for control of hospital cost for total knee arthroplasty. Clin Orthop 1997, 345:140-147.
25. 25 Knight JL, Sherer D, Guo J: Blood transfusion strategies for total knee arthroplasty: minimizing autologous blood wastage, risk of homologous blood transfusion, and transfusion cost., J Arthroplasty 1998, 13: 70-76. The authors develop an algorithm to provide cost-effective management of blood products after total knee arthroplasty.
26. 26 Ritter M, Mamlin LA, Melfi CA, Katz B, Freund DA, Arthur DS: Outcome implications for the timing of bilateral total knee arthroplasties. Clin Orthop 1997, 345:99-105.
27. 27 Lavernia CJ, Guzman JF, Gachupin-Garcia A: Cost effectiveness and quality of life in knee arthroplasty. Clin Orthop 1997, 345:134-139. Costs of a quality well year were estimated in 100 patients undergoing primary knee arthroplasty. The data indicate that the cost-effectiveness of this procedure compares favorably with that for other medical interventions such as coronary artery bypass surgery or renal dialysis.
28. 28 Yelin E: The earnings, income, and assets of persons aged 51-61 with and without musculoskeletal conditions. J Rheumatol 1997, 24:2024-2030. This report presents a comprehensive and comparative assessment of indirect costs in persons with versus those without musculoskeletal conditions. The former report 18% lower family earning, 15% lower family income, and 35% fewer assets than the age-adjusted average.
29. 29 Ruchlin HS, Elkin EB, MacKenzie CR, Williams-Russo P, Allegrante JP: Determining the cost of a clinical intervention through the use of shadow pricing. Arthritis Care Res 1997, 10:343-351.